U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07668479) titled 'Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan' on May 08.
Brief Summary: RIFA-REAL is a prospective observational longitudinal study evaluating the safety, feasibility, and effectiveness of rifapentine-based shorter treatment regimens for drug-susceptible tuberculosis (DS-TB) and tuberculosis infection (TBI) under routine programmatic conditions in Kazakhstan.
The study enrolls three cohorts: patients with DS-TB receiving the 4-month isoniazid-rifapentine-moxifloxacin-pyrazinamide regimen (2HPMZ/2HPM), patients with DS-TB receiving the standard 6-month isoniazid-rifampicin-pyrazinamide-ethambuto...